BPC-157 Biohacker and Longevity Stack Protocol: Doses, Routes, Cycles, and Evidence

What Is BPC-157 and Why Has the Longevity Community Adopted It?

BPC-157 stands for Body Protection Compound 157. It is a synthetic analog of a protein fragment isolated from human gastric juice, first characterized by researcher Predrag Sikiric at the University of Zagreb in the 1990s. The peptide is 15 amino acids long and is resistant to enzymatic degradation in the gut, which is why both oral and injectable forms are studied. Sikiric's foundational pharmacology work describes its stability and systemic distribution after oral administration in rats.

The longevity influencer community adopted BPC-157 primarily because of its consistent performance in rodent wound-healing and tendon-repair models. Figures in the Attia/Huberman/Brecka tier of health communication have cited these animal studies when discussing tissue-repair acceleration. The appeal is straightforward: aging tissues repair more slowly, so a compound that speeds repair in rats seems worth evaluating.

The Evidence Gap You Must Understand First

No completed, peer-reviewed, double-blind RCT in humans has demonstrated efficacy for BPC-157 in any indication. A search of ClinicalTrials.gov for BPC-157 returns a small number of early-phase or observational registrations, none of which have published efficacy results as of early 2025. Every protocol in this article is therefore built on rodent RCTs, in-vitro mechanistic data, and practitioner-reported experience. Those tiers are labeled explicitly throughout.

Regulatory Status

The FDA has not approved BPC-157 for any human use. In 2022, the FDA removed BPC-157 from the list of bulk substances that compounding pharmacies may use, citing the absence of clinical evidence of safety or effectiveness. The FDA's 2022 memo on peptide compounding places BPC-157 in Category 2, meaning it is not eligible for compounding under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Sourcing it from a compounding pharmacy in the United States is therefore outside current regulatory standards.

How BPC-157 Works: Mechanisms Behind the Longevity Interest

The three mechanisms cited most often in the peer-reviewed animal literature are nitric oxide (NO) pathway modulation, angiogenesis upregulation, and growth-hormone receptor sensitization in tendons and ligaments.

Nitric-Oxide Pathway Modulation

A 2016 study published in the Journal of Physiology and Pharmacology showed that BPC-157 counteracts the vasoconstriction induced by L-NAME (an NO synthase inhibitor) in rats, suggesting direct interaction with the NO signaling axis. Sikiric et al. (2016) demonstrated that BPC-157 maintained superior mesenteric artery blood flow even under pharmacological NO blockade, an effect that did not occur with saline controls (P<0.001 in vessel diameter measurements). This is the primary mechanistic argument for BPC-157's tissue-perfusion benefits. Evidence tier: Level 2 animal RCT.

Angiogenesis and Wound Healing

Hsieh et al. (2017) found that BPC-157 increased VEGF expression and accelerated vascularization in a rat Achilles tendon transection model. Tendons in the BPC-157 group showed statistically superior organization of collagen fibers at day 30 compared to controls (P<0.05). The biohacker community reads this as relevant to soft-tissue recovery after training stress. Evidence tier: Level 2 animal RCT.

Growth-Hormone Receptor Upregulation in Tendons

Chang et al. (2011) demonstrated that BPC-157 upregulates growth-hormone receptor (GHR) expression in tendon fibroblasts in a dose-dependent manner, which may explain accelerated collagen synthesis independent of circulating IGF-1 levels. This finding is particularly relevant for longevity stackers who are not on exogenous GH. Evidence tier: Level 2 animal study (in vitro and in vivo combined).

Biohacker Stack Protocol: Dose, Route, and Frequency

The following protocol synthesizes the most commonly cited practitioner frameworks in the longevity community and applies conservative dose ceilings consistent with the rodent safety literature. It is not a prescription. Use requires physician oversight.

Subcutaneous Injection Protocol (Most Common Route)

Starting dose: 250 mcg per day, injected subcutaneously near the site of injury or in the periumbilical region for systemic effect.

Titration: After 7 to 10 days with no adverse reaction, some practitioners increase to 500 mcg per day. Rodent studies use weight-based dosing of approximately 10 mcg/kg; a 75 kg adult extrapolates to 750 mcg/day, but the biohacker community generally stays at or below 500 mcg to limit risk exposure given zero human safety RCTs.

Frequency: Once daily. Most animal studies use single daily injections rather than split dosing, so this mirrors the experimental design most directly.

Reconstitution: BPC-157 is typically supplied as a lyophilized powder. Standard reconstitution uses bacteriostatic water at a concentration of 500 mcg/mL, giving 1 mL per 500 mcg dose with a 29 to 31 gauge insulin syringe.

Injection site rotation: Rotate sites across the abdomen to prevent local lipohypertrophy, the same practice used in insulin therapy. FDA insulin guidance on site rotation provides the clinical rationale for this practice.

Oral Administration Protocol (Lower Bioavailability, No Injection Required)

BPC-157 was originally characterized as a peptide stable in gastric acid, which makes oral dosing pharmacologically plausible for gastrointestinal-specific targets. Sikiric et al. (1993) showed that orally administered BPC-157 healed ethanol-induced gastric ulcers in rats at 10 mcg/kg, performing comparably to ranitidine.

Practitioners who target gut-healing specifically (leaky gut, IBD-adjacent presentations, NSAID-induced mucosal damage) often prefer oral capsules at 500 mcg, 1,000 mcg per day taken on an empty stomach. Systemic bioavailability for non-GI targets is likely lower than subcutaneous injection, though no human pharmacokinetic study exists to quantify the difference.

Cycle Length and Off-Period Rationale

The standard biohacker cycle is 4 to 12 weeks on, followed by a minimum 4-week off period. The rationale for cycling comes from receptor-downregulation theory rather than direct BPC-157 data. Given that BPC-157 may upregulate GHR expression, prolonged continuous use could theoretically alter receptor sensitivity, though this has not been demonstrated in the BPC-157 literature specifically. The conservative approach mirrors cycling conventions used with other research peptides like CJC-1295, where continuous vs. Pulsed GH secretagogue administration has been studied in humans.

Stacking BPC-157: Common Longevity Combinations

The longevity community rarely uses BPC-157 in isolation. The two most discussed stacking partners are TB-500 and NAD+ precursors.

BPC-157 Plus TB-500 (The "Wolverine Stack")

TB-500 is a synthetic fragment of thymosin beta-4 (the Ac-SDKP fragment). It promotes actin polymerization and cell migration to injury sites. Goldstein et al. (2012) reviewed thymosin beta-4's role in cardiac and wound repair, noting mechanistically distinct but complementary pathways from BPC-157's NO-driven angiogenesis.

The theoretical combination: BPC-157 drives vascularization and NO-mediated perfusion; TB-500 drives cell recruitment and actin-dependent tissue remodeling. They operate on different molecular axes, which is why practitioners combine them rather than doubling the dose of one. Typical combined protocol: BPC-157 250 mcg/day subcutaneous + TB-500 2 to 5 mg twice weekly subcutaneous for 4 to 6 weeks. Evidence tier for combined use: anecdotal practitioner experience only. No comparative animal or human study has evaluated the combination directly.

BPC-157 Plus NAD+ Precursors

Some longevity protocols layer BPC-157 on top of NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) supplementation. The mechanistic argument links BPC-157's tissue-repair effects with NAD+-dependent SIRT1/PARP1 activity in DNA repair. Yoshino et al. (2021) published the first double-blind RCT showing NMN supplementation (250 mg/day) improved muscle insulin sensitivity in postmenopausal women (N=25, 10-week trial). BPC-157 does not share NAD+ metabolism, so the stack is additive rather than synergistic at a mechanistic level. The combination is popular in longevity communities primarily because both compounds target tissue maintenance, not because of any interaction data.

What Not to Stack

Practitioners consistently advise against combining BPC-157 with high-dose NSAIDs during the cycle. BPC-157's gastroprotective effects in animals are attributed partly to NO-mediated mucosal protection, the same pathway that NSAIDs suppress. Wallace et al. (2010) demonstrated that NSAID-induced gastrointestinal injury involves NO-pathway disruption, providing a pharmacological reason to avoid this combination even in the absence of direct BPC-157 interaction data.

Monitoring Labs for BPC-157 Users

Physician-supervised use should include baseline and follow-up labs. No BPC-157-specific biomarker exists, so monitoring targets general safety and downstream effects.

Baseline Labs (Before Starting)

| Lab Panel | Rationale | |---|---| | Comprehensive metabolic panel (CMP) | Renal and hepatic safety baseline | | CBC with differential | Hematologic baseline | | High-sensitivity CRP | Inflammatory baseline to track change | | Fasting insulin and glucose | Metabolic baseline; BPC-157 modulates insulin signaling in rodents | | IGF-1 | Baseline before any GHR-modulating peptide | | Lipid panel | Cardiovascular baseline |

Follow-Up Labs (4 to 6 Weeks Into Cycle)

Repeat CMP, CRP, fasting insulin, and IGF-1. A meaningful IGF-1 rise (>30 ng/mL above baseline) without exogenous GH or GH secretagogue use may indicate stronger-than-expected GHR upregulation and warrants pausing the protocol.

The Endocrine Society's clinical practice guideline on IGF-1 interpretation provides reference ranges and clinical decision thresholds that a reviewing physician should use when evaluating follow-up results.

Expected Timeline of Subjective and Objective Outcomes

The following timeline is derived from rodent study endpoints translated to human experience by practitioners. It is anecdotal extrapolation, not human clinical data.

Weeks 1 to 2: Some users report improved sleep quality and reduced joint discomfort. Mechanistically plausible given NO-mediated vasodilation improving tissue perfusion.

Weeks 2 to 4: Practitioners most commonly report accelerated recovery from training-induced muscle soreness and early improvements in soft-tissue injury symptoms (tendinopathy, partial ligament sprains). This aligns with the 30-day rodent Achilles tendon endpoints in Hsieh et al. (2017).

Weeks 4 to 8: Reported improvements in gut comfort in users with baseline GI complaints. Consistent with the oral BPC-157 gastric ulcer data in rodents from Sikiric et al. (1993).

Week 12 and beyond: No rodent data supports extending beyond 12 weeks, and receptor-downregulation theory argues for cycling off.

Safety Profile and Known Risks

BPC-157 has shown a low adverse-event profile in animal studies, but the absence of human RCT data means the true human safety profile is unknown.

What Animal Studies Show

Across multiple rodent studies, BPC-157 at doses up to 10 mcg/kg produced no organ toxicity on necropsy, no significant hematologic changes, and no behavioral abnormalities. Sikiric et al. (2018) reviewed the compound's safety across 30 years of Zagreb laboratory work and reported no LD50 could be established in rats, meaning a lethal dose was not reached at any tested amount.

The Oncology Concern

BPC-157 promotes angiogenesis and upregulates growth factors. Any compound that promotes vascular growth raises a theoretical question about tumor promotion. No rodent study has demonstrated tumor promotion with BPC-157. However, individuals with a personal or family history of hormone-sensitive or vascular-dependent cancers should not use BPC-157 without explicit oncology consultation. This is not a documented risk; it is a mechanistically grounded caution. The NCI's overview of angiogenesis in cancer contextualizes why angiogenic compounds warrant this consideration.

Injection-Site Reactions

Subcutaneous injections may cause transient erythema, mild induration, or bruising at the site. These are technique-dependent and are not compound-specific adverse effects.

Evidence Tier Summary Table

| Claim | Evidence Tier | Key Citation | |---|---|---| | BPC-157 heals gastric ulcers in rats | Level 2 animal RCT | Sikiric et al. 1993 | | BPC-157 accelerates Achilles tendon repair in rats | Level 2 animal RCT | Hsieh et al. 2017 | | BPC-157 upregulates GHR in tendon fibroblasts | Level 3 animal/in vitro | Chang et al. 2011 | | BPC-157 modulates NO pathway in vivo | Level 2 animal RCT | Sikiric et al. 2016 | | 250 to 500 mcg/day subcutaneous is safe in humans | No human RCT | Practitioner extrapolation | | BPC-157 + TB-500 combination | No controlled data | Anecdotal/theoretical | | 4 to 12 week cycle is optimal | No BPC-157-specific data | Extrapolated from GH secretagogue cycling |